Many Sage Therapeutics, Inc.(SAGE) Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock. SAGE Therapeutics Inc was Upgraded by Chardan Capital Markets on Feb 14, 2017 to Neutral, Price Target of the shares are set at $60.SAGE Therapeutics Inc was Upgraded by Raymond James on Dec 14, 2016 to Strong Buy, Price Target of the shares are set at $84.
Company has reported several Insider transactions to the SEC, on Jan 13, 2017, Kimi Iguchi (CFO, Secretary and Treasurer) sold 10,000 shares at 53.92 per share price.On Jul 14, 2016, Albert Robichaud (Chief Scientific Officer) sold 22,000 shares at 40.00 per share price.On May 18, 2016, Kevin P Starr (director 10% owner) sold 850,000 shares at 31.25 per share price.
Sage Therapeutics, Inc. (NASDAQ:SAGE) has received a short term rating of hold from experts at Zacks with a rank of 3. The stock has been rated an average of 1.44 by 9 Brokerage Firm. 8 Wall Street Firms have rated the stock as a strong buys. 1 Analysts have rated it as strong sell.
Sage Therapeutics, Inc. (NASDAQ:SAGE) stock has received a short term price target of $ 73.22 from 9 Analyst. The share price can be expected to fluctuate from the mean short term target, can be seen from the standard deviation reading of $24.23. The higher estimate of target price is $95 , while the lower price target estimate is $18
Sage Therapeutics, Inc. (NASDAQ:SAGE) rose 2.53% or 1.34 points on Tuesday and made its way into the gainers of the day. After trading began at $53 the stock was seen hitting $55.16 as a peak level and $53 as the lowest level. The stock ended up at $54.33. The daily volume was measured at 980,151 shares. The 52-week high of the share price is $56.45 and the 52-week low is $26.2801. The company has a market cap of $2,019 million.
SAGE Therapeutics Inc. is a biopharmaceutical company developing and commercializing medicines to treat life-threatening central nervous system (CNS) disorders. The Company provides treatments for schizophrenia, major depressive disorder, pain, and traumatic brain injury conditions. Its initial product candidates include SAGE-547, SAGE-689 and SAGE-217. SAGE Therapeutics, Inc. is based in Cambridge, Massachusetts.